missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ NOV Polyclonal Antibody

Description
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
NOV is a member of the CCN family of secreted, cysteine-rich regulatory proteins. The full-length NOV protein contains four structural domains that confer distinct, and sometimes opposing, biological activities. Elevated expression of NOV is associated with certain tumors, including Wilm's tumor and most nephroblastomas. However, in other tumor types and certain cancer cell lines, increased tumorigenicity and proliferation is correlated with decreased NOV expression. Additionally, NOV induces cell adhesion and cell migration by signaling through specific cell-surface integrins, and by binding to heparin sulfate proteoglycans and to fibulin 1C. NOV has also been reported to exert proangiogenic activities.
Specifications
Specifications
| Antigen | NOV |
| Applications | Immunohistochemistry (Paraffin) |
| Classification | Polyclonal |
| Concentration | 1 mg/mL |
| Conjugate | Unconjugated |
| Formulation | PBS with 50% glycerol and 0.02% sodium azide; pH 7.2 |
| Gene | CCN3 |
| Gene Accession No. | P48745 |
| Gene Alias | C130088N23Rik; CCN family member 3; CCN3; Cellular communication network factor 3; IBP-9; IGF-binding protein 9; IGFBP9; IGFBP-9; Insulin-like growth factor-binding protein 9; Nephro blastoma-overexpressed gene protein homolog; nephroblastoma overexpressed; nephroblastoma overexpressed gene; nephroblastoma overexpressed gene protein homolog; nephroblastoma-overexpressed gene protein homolog; NOV; NovH; protein NOV homolog |
| Gene Symbols | CCN3 |
| Show More |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?